Fractional photothermolysis-an update

Inja Bogdan Allemann, Joely Kaufman

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

The novel concept of non-ablative fractional photothermolysis was introduced to the market in 2003 as an answer to the need for effective, yet low risk, resurfacing techniques. Unlike conventional ablative and non-ablative lasers, fractional ablative and non-ablative photothermolysis treats only a fraction of the skin, leaving up to a maximum of 95% of the skin uninvolved. The undamaged surrounding tissue allows for a reservoir of viable tissue, permitting rapid epidermal repair. Non-ablative fractional photothermolysis is currently approved by the US Food and Drug Administration (FDA) for the treatment of pigmented lesions, periorbital rhytides, skin resurfacing, melasma and soft tissue coagulation, acne and surgical scars, and actinic keratoses. However, its off-label use is clearly more extended. In 2007 the concept was further developed, and ablative fractional photothermolysis was introduced, using an erbium yttrium aluminium garnet (Er:YAG) or carbon dioxide laser. These devices are FDA cleared to treat wrinkles, rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. In this review we discuss the two concepts, their technical details and clinical indications, and we describe the current literature available.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalLasers in Medical Science
Volume25
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

United States Food and Drug Administration
Skin
Erbium
Off-Label Use
Actinic Keratosis
Melanosis
Gas Lasers
Acne Vulgaris
Cicatrix
Blood Vessels
Lasers
Equipment and Supplies
Therapeutics
yttrium-aluminum-garnet

Keywords

  • Ablative fractional photothermolysis
  • Laser
  • Non-ablative fractional photothermolysis

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Fractional photothermolysis-an update. / Bogdan Allemann, Inja; Kaufman, Joely.

In: Lasers in Medical Science, Vol. 25, No. 1, 01.2010, p. 137-144.

Research output: Contribution to journalArticle

Bogdan Allemann, I & Kaufman, J 2010, 'Fractional photothermolysis-an update', Lasers in Medical Science, vol. 25, no. 1, pp. 137-144. https://doi.org/10.1007/s10103-009-0734-8
Bogdan Allemann, Inja ; Kaufman, Joely. / Fractional photothermolysis-an update. In: Lasers in Medical Science. 2010 ; Vol. 25, No. 1. pp. 137-144.
@article{511c0cfd8dd74c94abaca1d1db333008,
title = "Fractional photothermolysis-an update",
abstract = "The novel concept of non-ablative fractional photothermolysis was introduced to the market in 2003 as an answer to the need for effective, yet low risk, resurfacing techniques. Unlike conventional ablative and non-ablative lasers, fractional ablative and non-ablative photothermolysis treats only a fraction of the skin, leaving up to a maximum of 95{\%} of the skin uninvolved. The undamaged surrounding tissue allows for a reservoir of viable tissue, permitting rapid epidermal repair. Non-ablative fractional photothermolysis is currently approved by the US Food and Drug Administration (FDA) for the treatment of pigmented lesions, periorbital rhytides, skin resurfacing, melasma and soft tissue coagulation, acne and surgical scars, and actinic keratoses. However, its off-label use is clearly more extended. In 2007 the concept was further developed, and ablative fractional photothermolysis was introduced, using an erbium yttrium aluminium garnet (Er:YAG) or carbon dioxide laser. These devices are FDA cleared to treat wrinkles, rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. In this review we discuss the two concepts, their technical details and clinical indications, and we describe the current literature available.",
keywords = "Ablative fractional photothermolysis, Laser, Non-ablative fractional photothermolysis",
author = "{Bogdan Allemann}, Inja and Joely Kaufman",
year = "2010",
month = "1",
doi = "10.1007/s10103-009-0734-8",
language = "English (US)",
volume = "25",
pages = "137--144",
journal = "Lasers in Medical Science",
issn = "0268-8921",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Fractional photothermolysis-an update

AU - Bogdan Allemann, Inja

AU - Kaufman, Joely

PY - 2010/1

Y1 - 2010/1

N2 - The novel concept of non-ablative fractional photothermolysis was introduced to the market in 2003 as an answer to the need for effective, yet low risk, resurfacing techniques. Unlike conventional ablative and non-ablative lasers, fractional ablative and non-ablative photothermolysis treats only a fraction of the skin, leaving up to a maximum of 95% of the skin uninvolved. The undamaged surrounding tissue allows for a reservoir of viable tissue, permitting rapid epidermal repair. Non-ablative fractional photothermolysis is currently approved by the US Food and Drug Administration (FDA) for the treatment of pigmented lesions, periorbital rhytides, skin resurfacing, melasma and soft tissue coagulation, acne and surgical scars, and actinic keratoses. However, its off-label use is clearly more extended. In 2007 the concept was further developed, and ablative fractional photothermolysis was introduced, using an erbium yttrium aluminium garnet (Er:YAG) or carbon dioxide laser. These devices are FDA cleared to treat wrinkles, rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. In this review we discuss the two concepts, their technical details and clinical indications, and we describe the current literature available.

AB - The novel concept of non-ablative fractional photothermolysis was introduced to the market in 2003 as an answer to the need for effective, yet low risk, resurfacing techniques. Unlike conventional ablative and non-ablative lasers, fractional ablative and non-ablative photothermolysis treats only a fraction of the skin, leaving up to a maximum of 95% of the skin uninvolved. The undamaged surrounding tissue allows for a reservoir of viable tissue, permitting rapid epidermal repair. Non-ablative fractional photothermolysis is currently approved by the US Food and Drug Administration (FDA) for the treatment of pigmented lesions, periorbital rhytides, skin resurfacing, melasma and soft tissue coagulation, acne and surgical scars, and actinic keratoses. However, its off-label use is clearly more extended. In 2007 the concept was further developed, and ablative fractional photothermolysis was introduced, using an erbium yttrium aluminium garnet (Er:YAG) or carbon dioxide laser. These devices are FDA cleared to treat wrinkles, rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. In this review we discuss the two concepts, their technical details and clinical indications, and we describe the current literature available.

KW - Ablative fractional photothermolysis

KW - Laser

KW - Non-ablative fractional photothermolysis

UR - http://www.scopus.com/inward/record.url?scp=72349085938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72349085938&partnerID=8YFLogxK

U2 - 10.1007/s10103-009-0734-8

DO - 10.1007/s10103-009-0734-8

M3 - Article

VL - 25

SP - 137

EP - 144

JO - Lasers in Medical Science

JF - Lasers in Medical Science

SN - 0268-8921

IS - 1

ER -